Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -49K | 0 | 0 | 0 | 0 |
| Operating Income | -75M | -55M | -63M | -27M | -1M |
| EBITDA | -75M | -55M | -63M | -27M | 8M |
| Net Income | -99M | -52M | -60M | -26M | 8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.75
+3.59% today
1Y Change
+231.86%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zura Bio Limited (ZURA) is a Healthcare stock with a market cap of $350.00M and listed on NASDAQ. The stock last traded around $3.75 and up 231.9% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -76.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -76.7%, free cash flow -130.6% with operating margin 0.0% and ROIC -74.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZURA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZURA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZURA Max Drawdown
-51.70%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZURA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
$8.4M
+132.7% YoY
Free Cash Flow
-$1.1M
+91.7% YoY
Revenue Growth
+0.0%
EPS Growth
-76.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -49K | 0 | 0 | 0 | 0 |
| Operating Income | -75M | -55M | -63M | -27M | -1M |
| EBITDA | -75M | -55M | -63M | -27M | 8M |
| Net Income | -99M | -52M | -60M | -26M | 8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | 109M | 176M | 100M | 2M | 729K |
| Total Assets | 114M | 180M | 101M | 5M | 141M |
| Total Liabilities | 12M | 20M | 21M | 27M | 10M |
| Shareholder Equity | 102M | 147M | 59M | -32M | 130M |
| Total Debt | 0 | 0 | 0 | 8M | 0 |
| Net Debt | -109M | -176M | -100M | 6M | -729K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+8.6% YoY
Capital Expenditures
4
+100.0% YoY
Free Cash Flow
1M
+91.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-83.9%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.